At the end of therapy, nebulized AB group (Group II) and nebulized + extended infusion AB group (Group III) compared to control group (Group I) showed higher incidence of clinical cure (53.33% patients in Group II and 66.67% patients in Group III vs. 26.67% patients in Group I; P = 0.007); the results were statistically significant.
Group II -IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h in addition to nebulized amikacin 25 mg/kg/day every 8 h. Group III received IV amikacin 20 mg/kg/24 h, nebulized amikacin 25 mg/kg/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h/8 h 
Group I - IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h.
incidence of clinical cure